Results from the CORE I trial of Uceris (budesonide) in ulcerative colitis appeared in Gastroenterology, detailing a statistically significant benefit over placebo for inducing remission of the disease. Read More
The romantic view of pregnancy is that it is the most precious nine months of a woman's life. A more prosaic view is that it is an autoimmune disease waiting to happen. Read More
CEO Sapan Shah calls ARMGO Pharma Inc. "one of biotech's better-kept secrets," but news about the company has begun to leak – not unlike the faulty calcium channels in diseased tissue that ARMGO's Phase II drug candidates are designed to fix. Read More
• BioLineRx Ltd., of Jerusalem, signed a purchase agreement for the sale, from time to time for up to 36 months, of up to $15 million of its American depositary shares (ADSs) with Lincoln Park Capital Fund LLC. Read More
• Discovery Laboratories Inc., of Warrington, Pa., began four research projects with its KL4 sufractant technology for acute lung injury. The preclinical studies will be in collaboration with research institutions, and funded through U.S. government-sponsored biodefense initiatives. Read More
• BioMarin Pharmaceutical Inc., of Novato, Calif., said it completed a Phase I study of BMN-111, an analogue of C-type natriuretic peptide, for achondroplasia, the most common form of human dwarfism. Read More
• Forest Laboratories Inc., of New York, and Pierre Fabre Laboratories, of Castres, France, said Forest submitted a new drug application for levomilnacipran, a serotonin norephinephrine reuptake inhibitor, for the treatment of major depressive disorder in adults. Read More
• Clarus Therapeutics Inc., of Northbrook, Ill., was issued U.S. Patent No. 8,241,664, "Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same," related to its testosterone product, CLR-610. Read More
